Mitotech’s management team has decades of expertise and experience in drug development, finance, biological research and start-up management. The multinational team brings a fresh perspective on the way science and clinical development can transform ophthalmology.
CEO: Natalia Perekhvatova, MS, MBA
Natalia Perekhvatova leads company’s growth, transforming the company from a drug discovery start-up to a dynamic clinical-stage biotech. She joined Mitotech as Chief Financial Officer in 2010. Prior to Mitotech she worked extensively in the financial sector and in IT infrastructure, including senior positions at Citigroup and Amadeus. She has an MBA degree from INSEAD, France and MS degree in Applied Mathematics from the Moscow State University, Russia.
CFO: John M. Barberich
John Barberich is an experienced healthcare CFO, business developer and investor. He was co-founder and Chief Financial Officer of ACADIA Pharmaceuticals (ACAD), CFO and Director of Omrix Biopharmaceuticals (now J&J), CFO Scriptgen Pharmaceuticals (now Roche), acting Chief Business/Finance Officer of Lumos Pharma (LUMO) and a Venture Partner with Nordic Biotech
CCO: Lawrence Friedhoff, MD, PhD, FACP
Lawrence Friedhoff joined Mitotech as a Chief Clinical Officer in 2014 to lead the company’s pre-clinical and clinical development programs in the U.S. and Europe. In a 30-year pharmaceutical industry career, he managed the development of six FDA-approved products that generate annual sales totalling over $4 billion. Before joining Mitotech, Dr. Friedhoff led clinical development at a number of pharmaceutical and biotechnology companies including Bristol-Myers Squibb, Eisai, Andrx Laboratories and Axovant. His academic career includes positions at Cornell Graduate School of Medical Science and Sloan-Kettering Institute. Dr. Friedhoff holds MD degree from NYU School of Medicine and PhD degree from Columbia University.
Head of CMC: Dr. Bhagwati Kabra
Bhagwati Kabra is a seasoned ophthalmology formulation expert who leads CMC operations and drug product manufacturing at Mitotech. During his extensive career at Alcon and Novartis he headed CMC development and registration of a spectrum of ophthalmology products: Pazeo®, Simbrinza®, Ilevero®, Izba®, Systane®, Beovu®
CSO: Maxim Skulachev, PhD
Maxim Skulachev manages Mitotech’s scientific research. With multiple scientific teams under his supervision and collaborations with many partner laboratories, Dr Skulachev’s efforts provide our company with valuable competitive advantage. His academic career focused on mitochondria targeting of small molecules has been based at the Moscow State University, Russia, where he received his PhD.
COO: Anton Petrov, PhD, MBA
Anton Petrov has been Chief Operating Office of Mitotech since the company’s inception. He supervises the operations behind Mitotech's drug development process in the U.S. and EU, concentrating on preclinical and clinical segments. He has worked in biotechnology for two decades, and held management positions at several biotech start-ups prior to joining Mitotech. He received his PhD from the University of Southern California and obtained his MBA from INSEAD, France.